NB-006 is a best-in-class modified-release formulation of ramelteon for insomnia characterized by difficulty with sleep onset and early awakening. This oral tablet targets the $5B insomnia market with FDA and NMPA IND approval and robust patent protection (CN: 202110950477.6; US18/288382).
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.